Table 2. Bivariate analysis of parameters associated with hospitalization for any cause in children with indication for the use of palivizumab, Porto Alegre, 2017.
| Hospitalization for any cause | OR (95% CI) | p | ||
|---|---|---|---|---|
| Yes n (%) | No n (%) | |||
| Use of prophylactic palivizumab | ||||
| Yes | 26 (37.7) | 43 (62.3) | 1.0 | |
| No | 34 (56.7) | 26 (43.3) | 0.46 (0.23 - 0.94) | 0.032 |
| Sex | ||||
| Female | 32 (45.7) | 38 (54.3) | 1.0 | |
| Male | 28 (47.5) | 31 (52.5) | 1.07 (0.54 - 2.15) | 0.843 |
| Place of residence | ||||
| Porto Alegre | 35 (44.3) | 44 (55.7) | 1.0 | |
| Another city | 25 (50.0) | 25 (50.0) | 1.26 (0.62 - 2.56) | 0.528 |
| Number of people in household | ||||
| Up to 3 people | 09 (37.5) | 15 (62.5) | 1.0 | |
| 4 people or more | 22 (37.9) | 36 (62.1) | 1.02 (0.38 - 2.72) | 0.971 |
| Main reason for inclusion in the study | ||||
| Prematurity | 46 (50.5) | 45 (49.5) | 1.0 | |
| Lung or heart disease | 14 (36.8) | 24 (63.2) | 0.57 (0.26 - 1.24) | 0.157 |
| Breastfeeding records | ||||
| Yes | 43 (47.2) | 48 (52.8) | 1.0 | |
| No | 09 (45.0) | 11 (55.0) | 0.91 (0.34 - 2.41) | 0.855 |
| For those who used PVZ: | ||||
| Number of doses administered | ||||
| Three or more | 21 (38.9) | 33 (61.1) | 1.0 | |
| Up to two | 05 (33.3) | 10 (66.7) | 0.78 (0.23 – 2.62) | 0.695 |
*Adjusted per year of entry into the study